Paxalisib
- Generic Name
- Paxalisib
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C18H22N8O2
- CAS Number
- 1382979-44-3
- Unique Ingredient Identifier
- P5DKZ70636
- Background
GDC-0084 is under investigation in clinical trial NCT03696355 (Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas).
- Associated Conditions
- -
- Associated Therapies
- -
Paxalisib With a High Fat, Low Carb Diet and Metformin for Glioblastoma
- Conditions
- Interventions
- First Posted Date
- 2022-01-10
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 33
- Registration Number
- NCT05183204
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
Combination Therapy for the Treatment of Diffuse Midline Gliomas
- Conditions
- Interventions
- First Posted Date
- 2021-08-18
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 360
- Registration Number
- NCT05009992
- Locations
- 🇨ðŸ‡
The University Children's Hospital in Zurich, Zürich, Switzerland
🇺🇸Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸University of Utah, Salt Lake City, Utah, United States
Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL
- Conditions
- Interventions
- First Posted Date
- 2021-05-28
- Last Posted Date
- 2024-05-17
- Lead Sponsor
- Lakshmi Nayak, MD
- Target Recruit Count
- 25
- Registration Number
- NCT04906096
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma
- First Posted Date
- 2019-05-31
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Global Coalition for Adaptive Research
- Target Recruit Count
- 1030
- Registration Number
- NCT03970447
- Locations
- 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸University of California, San Diego, La Jolla, California, United States
🇺🇸Cedars Sinai - Samuel Oschin Comprehensive Cancer Institute, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.